Drugs / BBP-671
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04836494 | Mar 2021 → Nov 2023 | disorder of organic acid metabolism, methylmalonic acidemia, propionic acidemia | CoA Therapeutics, Inc., a BridgeBio company | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-26 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma presents positive phase 1 data in healthy volunteers, advancing development of bbp-671 for pantothenate kinase-associated neurodegeneration (pkan) and organic acidemias bridgebio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-08-18 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma announces dosing of first patient in phase 1 trial of bbp-671, a potential best-in-class treatment for propionic acidemia (pa) and methylmalonic acidemia (mma) bridgebio.com ↗ |
| 2022-05-26 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma presents positive phase 1 data in healthy volunteers, advancing development of bbp-671 for pantothenate kinase-associated neurodegeneration (pkan) and organic acidemias bridgebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBP-671 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04836494 ↗ |
| Action | Activate | “BBP-671, an allosteric activator of pantothenate kinases” PMID 37875310 ↗ Jan 2024 |
| Route | Oral | “orally administered BBP-671” PMID 37875310 ↗ Jan 2024 |